Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verducatib in Healthy Chinese Participants
NCT07531628Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verducatib, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from time 0 to 24 hours, Maximum measured concentration at 24 hours and 2 more. Started Jun 2026; status: completed.
02
Drugs
verducatib
Beyond the preview
Go deeper on NCT07531628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07531628.